Genelux Corporation
GNLXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Genelux Corporation focuses on Biotechnology services and products. Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor. The $128.7M market capitalization puts GNLX squarely in micro-cap range for its industry. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Market Cap
$128.7M
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
-3.77
EPS (TTM)
$-0.85
EPS (Fwd)
$-0.76
ROE
-127.3%
ROA
-60.6%
Cash
$26.2M
Total Debt
$2.5M
Free CF
-$15.3M
52W Change
-13.8%
Annual Financials
Cash vs Debt
With $26.2M in cash and $2.5M in debt, GNLX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$15.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -127.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $11.1M (2022) to $8K (2025), a 100% decline worth watching.
GNLX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, GNLX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GNLX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.